Earl St. Rose
About
Earl St. Rose is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Pharmacology.
According to data from OpenAlex, Earl St. Rose has authored 47 papers receiving a total of 894 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pulmonary and Respiratory Medicine, 19 papers in Physiology and 4 papers in Pharmacology. Recurrent topics in Earl St. Rose's work include Chronic Obstructive Pulmonary Disease (COPD) Research (32 papers), Inhalation and Respiratory Drug Delivery (31 papers) and Asthma and respiratory diseases (19 papers). Earl St. Rose is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (32 papers), Inhalation and Respiratory Drug Delivery (31 papers) and Asthma and respiratory diseases (19 papers). Earl St. Rose collaborates with scholars based in United States, United Kingdom and Germany. Earl St. Rose's co-authors include Colin Reisner, Patrick Darken, Gary T. Ferguson, Klaus F. Rabe, Paul Dorinsky, Roopa Trivedi, Shaila Ballal, Dave Singh, Chen Wang and Magnus Aurivillius and has published in prestigious journals such as New England Journal of Medicine, American Journal of Respiratory and Critical Care Medicine and European Respiratory Journal.
In The Last Decade
Earl St. Rose
44 papers receiving 852 citations
Hit Papers
Peers
Earl St. Rose
Wendy Bullington United States
Claudio M. Sanguinetti Italy
Frank Barnhart United States
Shireen Mirza United States
Andrea Morris United States
Walter Baigelman United States
R. C. Lowry United Kingdom
Sally Kilbride United States
Κonstantinos Bartziokas Greece
Andréanne Côté Canada
Citations per year, relative to Earl St. Rose Earl St. Rose (= 1×)
peers
Wendy Bullington
Countries citing papers authored by Earl St. Rose
Since
Specialization
Citations
This map shows the geographic impact of Earl St. Rose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Earl St. Rose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Earl St. Rose more than expected).
Fields of papers citing papers by Earl St. Rose
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Earl St. Rose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Earl St. Rose. The network helps show where Earl St. Rose may publish in the future.
Co-authorship network of co-authors of Earl St. Rose
This figure shows the co-authorship network connecting the top 25 collaborators of Earl St. Rose. A scholar is included among the top collaborators of Earl St. Rose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Earl St. Rose. Earl St. Rose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Martínez, Fernando J., Klaus F. Rabe, Gary T. Ferguson, et al.. (2020). Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. American Journal of Respiratory and Critical Care Medicine. 203(5). 553–564.
2.
Rabe, Klaus F., Fernando J. Martínez, Gary T. Ferguson, et al.. (2020). Single-Inhaler Triple Combination Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) at Two Corticosteroid Dose Levels in COPD: ETHOS Trial. A2493–A2493.
3.
Martínez, Fernando J., Klaus F. Rabe, Gary T. Ferguson, et al.. (2020). Benefits of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) on Symptoms and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease (COPD) in the ETHOS Trial. A5073–A5073.
4.
Rabe, Klaus F., Fernando J. Martínez, Gary T. Ferguson, et al.. (2019). A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. Respiratory Medicine. 158. 59–66.
5.
Darken, Patrick, Paolo B. DePetrillo, Colin Reisner, Earl St. Rose, & Paul Dorinsky. (2018). The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults. Pulmonary Pharmacology & Therapeutics. 50. 11–18.
6.
Fukushima, Yasushi, Yuji Nakatani, Yumiko Ide, et al.. (2018). Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD. International Journal of COPD. Volume 13. 1187–1194.
7.
Kerwin, Edward, Thomas M. Siler, Samir Arora, et al.. (2018). Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD. International Journal of COPD. Volume 13. 1483–1494.
8.
Feldman, Gregory, Faisal Fakih, Peter Mack, et al.. (2018). An Open-Label Study Evaluating the Performance of the Dose Indicator in a Metered Dose Inhaler Delivering Glycopyrrolate and Formoterol Fumarate in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 32(1). 40–46.
9.
Kerwin, Edward, et al.. (2018). A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD. Respiratory Research. 19(1). 38–38.
10.
Reisner, Colin, et al.. (2018). Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD. International Journal of COPD. Volume 13. 1965–1977.
11.
Reisner, Colin, Leonardo M. Fabbri, Edward Kerwin, et al.. (2017). A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease. Respiratory Research. 18(1). 158–158.
12.
Fabbri, Leonardo M., Edward Kerwin, Selwyn Spangenthal, et al.. (2016). Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD. Respiratory Research. 17(1). 109–109.
13.
Tashkin, Donald P., Fernando J. Martínez, Roberto Rodríguez-Roisin, et al.. (2016). A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD. Respiratory Medicine. 120. 16–24.
14.
Sethi, Sanjay, Charles Fogarty, Nicola A. Hanania, et al.. (2016). Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 4(1). 21–33.
15.
Quinn, Dean, J. Paul Seale, Colin Reisner, et al.. (2014). A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD. Respiratory Medicine. 108(9). 1327–1335.
16.
Reisner, Colin, Carlos Fernández‐Peña, Patrick Darken, et al.. (2014). Pearl's PT010 triple combination provides comparable budesonide exposure to symbicort and comparable glycopyrronium and formoterol exposure to PT003. European Respiratory Journal. 44(Suppl 58). 1891–1891.
17.
Fabbri, Leonardo M., et al.. (2013). Pooled analyses of QTcF across six phase 2b studies with glycopyrrolate-formoterol fumarate (GFF) MDI (PT003), its components and active comparators. European Respiratory Journal. 42(Suppl 57). P759–P759.
18.
Reisner, Colin, et al.. (2011). Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD. European Respiratory Journal. 38(Suppl 55). p879–p879.
19.
Wilkening, Robert R., Ronald W. Ratcliffe, Kenneth J. Wildonger, et al.. (1999). Synthesis and activity of 2-(sulfonamido)methyl-carbapenems: Discovery of a novel, anti-MRSA 1,8-naphthosultam pharmacophore. Bioorganic & Medicinal Chemistry Letters. 9(5). 673–678.
20.
Ratcliffe, Ronald W., Robert R. Wilkening, Kenneth J. Wildonger, et al.. (1999). Synthesis and properties of 2-(naphthosultamyl)methyl-carbapenems with potent anti-MRSA activity: Discovery of L-786,392. Bioorganic & Medicinal Chemistry Letters. 9(5). 679–684.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Wendy Bullington Breakdown of academic impact, for papers by Claudio M. Sanguinetti Breakdown of academic impact, for papers by Frank Barnhart Breakdown of academic impact, for papers by Shireen Mirza Breakdown of academic impact, for papers by Andrea Morris Breakdown of academic impact, for papers by Walter Baigelman Breakdown of academic impact, for papers by R. C. Lowry Breakdown of academic impact, for papers by Sally Kilbride Breakdown of academic impact, for papers by Κonstantinos Bartziokas Breakdown of academic impact, for papers by Andréanne Côté